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a b s t r a c t
Hypothesis: Naturally derived or synthetic anticancer peptides (ACPs) have emerged as a new generation
of anticancer agents with higher selectivity for cancer cells and less propensity for drug resistance.
Despite the structural diversity of ACPs, a-helix is the most common secondary structure among them.
Herein we report the development of a new library of short cationic amphiphilic a-helical ACPs with
selective cytotoxicity against colorectal and cervical cancer.
Experiments: The peptides had a general formula C(XXYY)3 with C representing amino acid cysteine (pro-
viding a -SH group for molecular conjugation), X representing hydrophobic amino acids (isoleucine (I) or
leucine (L)), and Y representing cationic amino acids (arginine (R) or lysine (K)). Two variants of the pep-
tides were synthesized by adding additional Isoleucine residues to the C-terminal and replacing the N-
terminal cysteine with LC-propargylglycine (LC-G) to investigate the effect of N-terminal and C-
terminal variation on the anticancer activity. The structure and physicochemical properties of the pep-
tides were determined by RP-HPLC, LC-MS and CD spectroscopy. The cytotoxicity of the peptides in dif-
ferent cell lines was assessed by MTT test, cell proliferation assay and mitochondrial damage assay. The
mechanism of cell selectivity of the peptides was investigated by studying their interfacial behaviour at
the air/water and lipid/water interface using Langmuir trough.
https://doi.org/10.1016/j.jcis.2021.08.200
0021-9797/ 2021 The Author(s). Published by Elsevier Inc.
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Findings: The peptides consisting of K residues in their hydrophilic domains exhibited more selective
anticancer activity whereas the peptides containing R exhibited strong toxicity in normal cells. The anti-
cancer activity of the peptides was a function of their helical content and their hydrophobicity. Therefore,
the addition of two I residues at C-terminal enhanced the anticancer activity of the peptides by increasing
their hydrophobicity and their helical content. These two variants also exhibited strong anticancer activ-
ity against colorectal cancer multicellular tumour spheroids (MCTS). The higher toxicity of the peptides in
cancer cells compared to normal cells was the result of higher penetration into the negatively charged
cancer cell membranes, leading to higher cellular uptake, and their cytotoxic effect was mainly exerted
by damaging the mitochondrial membranes leading to apoptosis. The results from this study provide a
basis for rational design of new a-helical ACPs with enhanced anticancer activity and selectivity.
 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cancer is the second leading cause of death in the world and is
generally caused by ‘‘driver mutations” in the genes which are
involved in key cellular functions which enable the cancer cells
to evade growth suppression, resist cell death, and activate inva-
sion and metastasis [1–4]. The current cancer treatment strategies
mainly include chemotherapy, radiotherapy, surgery, and
immunotherapy. These treatment strategies often lack selectivity
for cancer cells which leads to adverse effects that significantly
reduce the quality of life of the patients and can lead to discontin-
uation of therapy [5–17,3,18–27] or may even induce life threaten-
ing hypersensitivity reactions [16,27,28]. Another major concern
with many of the currently available anticancer agents is develop-
ment of drug resistance which can lead to cancer relapse [5,29].
Hence, there is still an ongoing quest for development of alterna-
tive cost-effective anticancer therapies with selective toxicity to
cancer cells without causing damage to the normal healthy tissues,
and with lower propensity for resistance.
Recently, anticancer peptides (ACPs) have emerged as a new
alternative to conventional anticancer drugs. Naturally occurring
antimicrobial peptides (AMPs) or host defence peptides are an
essential component of the innate immunity against pathogens
in different organisms such as plants, insects, amphibians, and
mammals [30–34]. More recently, it has been evidenced that some
AMPs also possess selective anticancer activity suggesting them as
promising anticancer drugs [34–36]. The smaller size and higher
solubility of the ACPs compared to monoclonal antibodies provides
better pharmacokinetics, higher cellular uptake in the target tissue
and rapid clearance from the non-target tissues which is favour-
able for anticancer agents [35]. Despite the structural diversity
among ACPs, they all share some common structural features such
as short sequence (5–50 amino acid residues), positive charge and
amphiphilic nature which are essential to their biological activity
[30–34].
The higher selectivity of the ACPs for cancer cells over normal
cells is supposed to be attributed to the higher affinity of the catio-
nic peptides for the anionic membrane of the cancer cells com-
pared to the zwitterionic membrane of the normal mammalian
cells [30–34,36,37]. The presence of anionic phospholipids such
as phosphatidylserine (PS) and higher expression of anionic mole-
cules such as heparan sulfates and O-glycosylated mucins in the
outer leaflet of the cancer cell membranes renders them more neg-
atively charged than the membrane of the normal cells which are
mainly composed of zwitterionic lipids such as phosphatidyl-
choline (PC) and sphingomyelin [30–34,36,37]. This targeting
mechanism is not affected by the tumour heterogeneity and is less
prone to drug resistance which is a great advantage over the other
classes of anticancer drugs [31,33,34]. Over the last decade, various
types of naturally occurring or synthetic anticancer peptides have
been introduced as efficient anticancer therapies some of which
have found their way to clinical trials [31,38]. The high production
costs, poor bioavailability due to enzymatic proteolysis, and risk of
immunogenicity with naturally occurring ACPs has shifted the ACP
research towards the development of synthetic ACPs with
enhanced efficacy and improved physicochemical properties
[31,33,39–43]. The design strategies mainly include template mod-
ification, minimalist de novo design, combinatorial library technol-
ogy and in silico models [40,42,44–53].
Herein, we report the development of a new series of synthetic
a-helical anticancer peptides with selective anticancer activity
towards colorectal and cervical cancer cells and minimal toxicity
in human dermal fibroblasts. The peptides were designed using
minimalist de novo design strategy based on the basic structural
features required for a-helical ACPs. The cytotoxicity of the
designed anticancer peptides in normal and cancer cells was stud-
ied and compared. Furthermore, the surface activity of the
designed ACPs at the air/water interface and their interaction with
different types of lipid mono and bilayers as models of normal and
cancer cell membranes were studied to provide an insight into the
structure activity relationship of this group of peptides.
The general formula for this series of anticancer peptides is C
(XXYY)3, with C representing amino acid cysteine, X representing
hydrophobic amino acids (isoleucine (I) or leucine (L)), and Y rep-
resenting cationic amino acids (arginine (R) or lysine (K)). This
combination of hydrophobic and cationic amino acids in the repeat
unit was expected to confer a-helical conformation on the peptide
upon contact with amphiphilic membranes and the N-terminal
cysteine was added to improve the helical propensity [43,49].
Moreover, the cysteine residue provides a site for conjugation of
the peptide to other molecules via the -SH group. Two variants of
these peptides were designed by adding additional isoleucine resi-
dues to the C-terminal to further stabilize the peptide molecule
and to increase its hydrophobicity [43]. In one of the variants,
the N-terminal cysteine was replaced with LC-propargylglycine
(LC-G) to investigate the effect of N-terminal variation on the sta-
bility of the helical structure and the anticancer activity of this ser-
ies of peptides as N-terminal glycine is reported to be abundant in
AMPs [42,49,53]. Furthermore, all the peptides were amidated at
the C-terminal to increase the positive charge density which is
supposed to enhance their anticancer activity [42,52,54]. Although
this combination of hydrophobic and cationic amino acids has
been previously used for the development of AMPs/ACPs with
varying sizes and structures, the newly designed series of anti-
cancer peptides provided in this study have significant structural
differences from the previously reported AMPs/ACPs to enhance
their anticancer activity and improve their selectivity toward can-
cer cells. Also, we used a systematic approach by keeping the net
positive charge of the peptides constant while changing the amino
acid combination in order to investigate the effect of such struc-
tural changes on the hydrophobicity and helicity of the peptides
and consequently on their anticancer activity/selectivity. Although
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a-helical ACPs with various structures have been tested in differ-
ent cancer cell lines, the anticancer activity of this class of ACPs
against colorectal cancer cells has not been reported previously.
Another important aspect of our research is studying the anti-
cancer activity of the designed peptides in colorectal cancer 3D
multicellular tumor spheroids (MCTSs) which serve as a closer
mimic of tumors compared to 2D cell cultures. To the best of our
knowledge, there has been very few reports on efficacy of ACPs
in MCTSs and none on colorectal cancer MCTSs.
2. Materials & methods
2.1. Materials
The peptides were synthesized by GL Biochem (Shanghai) Ltd
and provided as lyophilized powders (Purity > 95%). The peptide
solutions were prepared by dissolving the peptide powders in
Milli-Q water (Millipore Reagent Water System, USA) and their
pH was adjusted to the desirable range using sodium hydroxide.
All the chemicals, reagents and organic solvents were sourced from
Merck (Sigma Aldrich), UK, with analytical grade. All chemicals had
purity  99 % and all organic solvents had purity  99.7 %. 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-
dipalmitoyl-sn-glycero-3-phospho-(10-rac-glycerol) (DPPG) were
purchased from Avanti Polar Lipids (USA), with purity  99 %.
The Dulbecco’s Modified Eagle Medium (DMEM), Phosphate buf-
fered saline (PBS), Fetal bovine serum (FBS), Trypsin, Penicillin
and streptomycin were all sourced from GIBCO (Thermo Fisher Sci-
entific, UK).
2.2. Determination of peptide sequence and purity
The peptide sequences and molecular weights were verified by
Liquid chromatography-Mass spectrometry (LC-MS) (QExactive
HF, Thermo FisherTM). The full MS scan from m/z = 375–1500 was
acquired in the Orbitrap at a resolution of 120,000. Subsequent
fragmentation was Top 2 in the HCD cell, with detection of ions
in the Orbitrap using centroid mode, with a resolution of 30,000.
The purity of the peptides was checked by reverse phase high per-
formance liquid chromatography (RP-HPLC) using Waters 2695
HPLC system, with Waters 2487 UV/Visible detector set at the
wavelength of 205 nm, Xbridge C18 column (4.6  250 mm) and
a mobile phase consisting of acetonitrile and trifluoroacetic acid
(TFA) in water (0.1 % V/V), with a gradient of acetonitrile from 5
to 95% over 20 mins at a flow rate of 1 mL/min.
2.3. Determination of peptide hydrophobicity
The hydrophobicity of the designed cationic amphiphilic pep-
tides was determined both theoretically using the relevant equa-
tions and experimentally using RP-HPLC retention times. The
mean hydrophobicity value for each peptide was calculated by








Where < H > is the mean hydrophobicity of the peptide
sequence, Hi is the hydrophobicity of the ith amino acid in the pep-
tide sequence and N is the number of amino acid residues [55,56].
The values of hydrophobicity for each amino acid were based on
the hydrophobicity scale by Fauchère and Pliska which uses the
octanol–water partition coefficients [57,58].
2.4. Determination of peptide secondary structure
The secondary structure of the peptides was determined by Cir-
cular Dichroism (CD) spectroscopy using a Jasco J-810 spectropo-
larimeter and a quartz cell of 1 cm path length. The samples
were scanned between the wavelength of 190–240 nm with a
scanning speed of 100 nm/min and the peptide concentration
was fixed at 10 mM. The CDmeasurements were performed on pep-
tides in aqueous solution and in three different types of curved sur-
faces: Sodium dodecyl sulfate (SDS) micelles, DPPG small
unilamellar vesicles (SUVs) and DPPC SUVs. Each sample was
scanned three times and the data were expressed as the average
of the three measurements. The mean residue molar ellipticity








Where hM is residue molar ellipticity (deg.cm
2.dmol1), hobs is
the observed ellipticity at a given wavelength (mdeg), MRW is resi-
due molecular weight obtained by dividing the molecular weight
of the peptide by the number of amino acid residues, c is the pep-
tide concentration (mg/mL), and l is the path length of the cell (cm)
[51,59–62]. The helical content of the peptides was calculated
using the following equation:
fH ¼ h½ 222 þ 2000
 
= h½ H222 ð3Þ
Where fH is the fraction of helix, [h]222 is the measured mean
residue molar ellipticity at 222 nm, and h½ H222 is the mean residue
molar ellipticity for 100% helical content at 222 nm which in this
case was 28400 deg.cm2.dmol1 based on the length of the pep-
tides [61–64].
2.5. Preparation of lipid vesicles
The DPPC and DPPG SUVs were prepared by the thin-film
hydration method. The lipids were dissolved in chloroform at a
concentration of 2 mg/mL, then the solvent was evaporated under
vacuum using a rotary evaporator (Heidolph Instruments GmbH &
CO). The resulting thin lipid film was rehydrated with phosphate
buffer (pH = 7.4) and then brought to the desired size by extrusion
using Avanti mini-Extruder (Avanti Polar Lipids, USA) containing a
polycarbonate membrane with a pore size of 200 nm. The SDS
micelles were simply prepared by dissolving SDS powder in
Milli-Q water at the concentration of 25 mM which is above the
critical micelle concentration of SDS. The size of the lipid vesicles
was measured by Dynamic Light Scattering (DLS) using ZetaPALS
zeta potential analyzer, Brookhaven instruments corporation, and
reported as the average of 6 scans.
2.6. Surface activity and interaction of the peptides with lipid
monolayers
The surface pressure measurements were performed using a
Langmuir trough (NIMA technology Ltd, Coventry, UK), with a
3 mL built-in Teflon trough and a Wilhelmy plate attached to the
pressure sensor. The trough was filled with 3 mL of PBS
(pH = 7.4), the peptide solution was injected underneath the buffer
surface using a Hamilton microsyringe and the changes to the sur-
face pressure at the air–water interface was recorded as a function
of time for 2 h. The surface activity of the peptides upon adsorption
at the air/water interface results in a decrease in the surface ten-
sion from that of pure water. The surface pressure (p) is defined
as the difference between the initial surface tension (c0) of the pure
water and the final surface tension (c) following adsorption of the
peptides at the air/water interface [40,65]:
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p ¼ c0  c ð4Þ
The interaction of the peptides with the lipid monolayers was
studied by monitoring the changes to the surface pressure of lipid
monolayers made of DPPG or DPPC. The lipid monolayers were
formed by spreading the lipid solution in chloroform (0.5 mg/mL)
at the air-buffer interface using a Hamilton microsyringe. After
allowing 20 min for the solvent to evaporate and the lipid mono-
layer to equilibrate, the peptide solution was injected underneath
the monolayer into the subphase with a final concentration of
20 mM and the changes to the surface pressure over time were
monitored for 2 h. The initial pressure of the lipid monolayer
was set to 28 mN/m which is close to the average cell membrane
resting pressure [42,54,66]. All the measurements were performed
in triplicate and the values were reported as the average of the
three runs.
2.7. Cytotoxicity tests
The cytotoxicity tests were performed in three different human
cell lines, HCT 116 colorectal adenocarcinoma cells, HeLa cervical
cancer cells, and Human dermal fibroblasts (HDFs). All cells were
cultured in DMEM enriched with 10% FBS and 1% antibiotic (100
U/mL penicillin and 100 lg/mL streptomycin) at 37 C under 5%
CO2. The cytotoxicity of the peptides in different cell lines was
assessed by MTT assay. The cells were cultured in 96 well plates
at a seeding density of 4000 cells/well and incubated with different
concentrations of the peptide solutions at 37 C. After 72 h the cells
were subjected to MTT assay following the standard protocols.
Briefly, 10 mL of MTT solution (5 mg/mL) was added to each well
and incubated at 37 C for 4 h. Subsequently, the cell culture media
was replaced with Dimethyl Sulfoxide (DMSO). The plates were
shaken for 15 min to allow for complete dissolution of the precip-
itated formazan dye and then the absorbance of formazan was
measured at 590 nm using a microplate reader (Varioskan FlashTM,
Thermo Fisher Scientific). Data were normalised using the absor-
bance of untreated cells as controls. All experiments were repeated
6 times and the values were reported as Mean ± SE.
The cytotoxicity of the peptides in different cell lines was fur-
ther investigated by cell proliferation assay. The cells were cul-
tured under the same experimental conditions described for MTT
assay, and incubated with the peptides (100 mM) for 72 h. Subse-
quently, the cells were stained with Hoechst 33342 and Flash Phal-
loidinTM Red 594 and imaged using high content fluorescent
automated widefield microscope (ImageXpress Micro System,
Molecular Devices, USA). In order to evaluate the cytotoxicity of
the cationic amphiphilic peptides in multicellular tumour spher-
oids (MCTSs) HCT 116 cells were cultured in ultra-low binding
96 well plates at a seeding density of 10,000 cells/well. The cells
were incubated for 24 h to allow for the formation of MCTSs, then
treated with the cationic amphiphilic peptides (at the concentra-
tion of 100 mM) and incubated for 72 h. Anticancer activity was
evaluated in terms of reduction in the size of the MCTSs as visual-
ized by brightfield microscopy. The MCTSs were also stained with
live-dead assay kit consisting of propidium iodide and Syto 9 and
then imaged by high content microscope.
2.8. Mitochondrial damage tests
The ability of the cationic amphiphilic peptides to damage the
mitochondrial membrane was assessed using JC-1 mitochondrial
probe (InvitrogenTM). The cells were cultured in 96 well plates at
a seeding density of 4000 cells/well and incubated with the pep-
tide solutions (20 mM) for 72 h. Subsequently, the cells were
stained with JC-1 following the manufacturer’s protocol. Briefly,
the cells were washed with PBS, then prewarmed (37C) fresh
media containing JC-1 (10 mg/mL) was added to the cells (100 mL/
well) and incubated at 37C for 15 min after which the media
was removed, the cells were washed again with PBS and then sub-
merged in PBS (100 mL/well). The live imaging was performed
using high content microscope with CY3 and FITC filters for the
red and green fluorescence emission respectively.
2.9. Data analysis
The quantitative data were analysed using Microsoft Excel
2016 and GraphPad Prism 8. All data were reported as
Mean ± SD or Mean ± SE of the repeats. For the correlation graphs
the data were subjected to linear regression analysis at 95% confi-
dence interval (a = 0.05) and values of p < 0.05 were used to deter-
mine the goodness of fit. The microscopic images were analysed
using MetaXpress software 5.3.01 (Molecular Devices, USA).
3. Results and discussion
3.1. Structures and physicochemical properties of the designed
peptides
The full peptide sequences and molecular weights are provided
in Table 1. The peptide sequences were confirmed by LC-MS and
the molecular weights measured by LC-MS were very close to
the theoretical molecular weights calculated for these peptide
sequences.
As can be seen from Table 1, the calculated mean hydrophobic-
ity values of the designed ACPs suggest a minor decrease to the
peptide hydrophobicity upon replacing lysine with arginine but a
more significant reduction in the hydrophobicity upon replace-
ment of isoleucine with leucine. On the contrary, the RP-HPLC
retention times indicated a different trend in the hydrophobicity
of the designed ACPs as both replacing lysine with arginine and
replacing isoleucine with leucine increased the hydrophobicity
and consequently the retention times of the peptides. This incon-
sistency between the theoretically predicted and the experimen-
tally measured hydrophobicity lies in the fact that the mean
hydrophobicity of a peptide is merely based on its amino acid com-
position and does not take into account other factors such as the
secondary structure. On the other hand, the RP-HPLC retention
times provide a more accurate real-time measure of the peptide
hydrophobicity as they reflect the strength of the interaction
between the peptide and the stationary phase [40,67–71]. It has
been well evidenced that the hydrophobic surface of the RP-HPLC
stationary phase (the C18 column) induces a-helical conformation
in the peptide chain which in return leads to stronger binding of
the nonpolar face of the a-helix to the column and a substantial
increase in the retention times compared to that predicted using
amino acid-based partition coefficients [40,67–71]. Hence the
higher hydrophobicity of the arginine-rich or leucine-rich peptides
is likely to be due to stronger a-helical conformation upon contact
with the hydrophobic surface of the stationary phase which is in
accordance with the observed helical content of these peptides as
determined by circular dichroism (Section 3.2). Similar observa-
tions have been reported by other studies showing poor correlation
between the theoretically computed hydrophobicity of the a-
helical peptides and the experimental hydrophobicity measured
by RP-HPLC indicating lack of accuracy of the theoretical calcula-
tion method and suggesting the RP-HPLC retention times as a more
realistic and accurate measure of the peptide hydrophobicity
[40,61,70,71].
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3.2. Secondary structure of the peptides
The CD spectra of the designed ACPs in aqueous solution and
upon contact with different types of curved hydrophobic surfaces
are provided in Fig. 1. As can be observed, all of the designed pep-
tides were unfolded in aqueous solution as denoted by the pres-
ence of a negative peak at 198–200 nm which is indicative of
random coil structure [39,40,42,62,72,73]. This is attributed to
the strong intermolecular hydrogen bonding between the peptides
and the water molecules as well as the electrostatic repulsion
between the adjacent positively charged arginine/lysine residues
[40,74]. However, upon contact with the curved hydrophobic sur-
faces (phospholipid SUVs or SDS micelles), the peptides adopted a-
helical structure denoted by a positive peak at 193 nm and nega-
tive peaks at 208 nm and 220–222 nm [39,40,42,59,62,73].
Although different peptides showed different degree of helicity in
different environments, they all showed a higher tendency for
forming a-helical structure in the anionic environment of DPPG
SUVs and SDS micelles compared to the zwitterionic environment
of DPPC SUVs except for IR-13. This is attributed to the cationic
nature of the peptides which favours interaction with the anionic
lipid bilayers over zwitterionic lipid bilayers. As a result, the polar
surface of the a-helix interacts with the hydrophilic heads of the
phospholipids or SDS through charge interaction and the nonpolar
surface of the a-helix is inserted into the lipid bilayer [40]. These
results are in agreement with the literature data reported for other
types of short cationic amphiphilic a-helical AMPs/ACPs and also
cell penetrating peptides (CPPs) which have unfolded random coil
structure in aqueous solution but fold into a-helix in SDS micelles
or negatively charged phospholipid vesicles such as DOPG and
DPPG [39,40,42,62,73,74].
The separation between the polar and nonpolar faces of the a-
helix could be well portrayed using the Schiffer-Edmundson Heli-
cal wheel projections (Fig. 1F). The helical wheels provide a two-
dimensional projection of the a-helix with separate hydrophobic
and hydrophilic surfaces [75]. The helical content of the peptides
in different types of hydrophobic curved surfaces could be com-
pared using the observed mean residue molar ellipticity at
222 nm (Fig. 1). Comparison of the helical content of different
cationic amphiphilic peptides in phospholipid bilayers revealed
that CI-15 and GI-15 had the highest helical content in DPPG SUVs
which indicates the role of the additional C-terminal isoleucine in
increasing the helical propensity of the peptide. The lower helicity
of GI-15 compared to CI-15 is supposed to be due to the presence
of LC-Propargylglycine instead of Cysteine in the N-terminal which
disfavours the helical formation. Similar findings have been
reported by Chen et al with regard to other short cationic amphi-
philic AMPs indicating the favourable effect of C-terminal isoleu-
cine and unfavourable effect of N-terminal glycine on the
formation and stabilization of the a-helical structure [52]. The
trend observed for the increase in helicity of the ACPs in SDS
micelles and DPPG SUVs was consistent with the trend observed
for the increase in RP-HPLC retention times (Fig. 1 G-H). The good
correlation between the helical content in curved hydrophobic sur-
faces and the retention times further confirms the significant effect
of the conformational change from random coil into a-helix upon
interaction with the hydrophobic surface of the stationary phase
Table 1
Sequences and chemical properties of the designed cationic amphiphilic peptides.
Peptide Sequence Charge Theoretical MWa Measured MWb RTc <H>d
IK-13 CIIKKIIKKIIKK-NH2 +6 1568.2 1568.1 10.0 0.49
LK-13 CLLKKLLKKLLKK-NH2 +6 1568.2 1568.1 10.8 0.45
IR-13 CIIRRIIRRIIRR-NH2 +6 1736.2 1736.3 9.5 0.48
LR-13 CLLRRLLRRLLRR-NH2 +6 1736.2 1736.3 11.3 0.44
CI-15 CIIKKIIKKIIKKII-NH2 +6 1794.4 1795.4 11.9 0.67
GI-15 LC-Propargyl-GIIKKIIKKIIKKII-NH2 +6 1786.4 1786.7 11.7 0.56
a, the theoretical molecular weights as calculated using the online tool from the website ‘‘https://pepcalc.com”; b, the real molecular weights as measured by LC-MS; c, the
HPLC retention times; d, the mean hydrophobicity values calculated by Eisenberg method using the hydrophobicity scale defined by Fauchère and Pliska.
Fig. 1. Secondary structure of the peptides. Circular dichroism spectra of the cationic amphiphilic peptides in DI water (A), SDS micelles (B), DPPC SUVs (C) and DPPG SUVs
(D). The data are reported as the average of 3 repeats. Helical content of the peptides in SDS, DPPC and DPPG SUVs (E). Schiffer-Edmundson Helical wheel projections of the
designed cationic amphiphilic peptides (F). The blue circles represent hydrophilic amino acids (K and R) and the yellow circles represent hydrophobic amino acids (I, L and C).
Drawn using the online tool of the website ‘‘https://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py”. Correlation between the degree of helicity of the peptides in SDS
micelles (G) or DPPG SUVs (H) and their apparent hydrophobicity as measured by RP-HPLC retention times.
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on the apparent hydrophobicity of the cationic amphiphilic pep-
tides as reported elsewhere [40,61,71].
3.3. Cytotoxicity of the ACPs in normal and cancer cells
The cytotoxicity of the designed ACPs against cancer cells and
normal cells as determined by MTT assay are presented in Fig. 2
and the values of half maximal inhibitory concentration (IC50) cal-
culated using the concentration–response curves are provided in
Table 2. As it could be observed, there was a marked difference
between the cytotoxicity of the cationic amphiphilic peptides in
cancer cell lines (HCT 116 and HeLa) and human dermal fibroblasts
(HDF). IK-13, CI-15 and GI-15 were considerably more toxic to can-
cer cells compared to fibroblasts, indicating their selective anti-
cancer activity, whereas IR-13 and LR-13 were highly toxic to
fibroblasts. Thus, replacing the lysine residues with arginine resi-
dues in the hydrophilic domain of the designed ACPs increased
their toxicity against normal cells. Moreover, in the case of IR-13,
it also diminished its toxicity against cancer cells. LK-13 was selec-
tively toxic to HCT 116 but had very poor toxicity against HeLa sug-
gesting the importance of the isoleucine residues in the
hydrophobic domain for toxicity against HeLa. These observations
suggest the importance of scanning different ACPs in different can-
cer cell lines for optimising the anticancer effect of the ACPs. The
strong anticancer activity of CI-15 and GI-15 compared to the other
peptides in this series is mainly attributed to the presence of the
additional isoleucine residues in their C-terminal resulting in
higher helical content in anionic environments such as negatively
charged cancer cell membranes which can increase their cell pen-
etration. The higher overall hydrophobicity of these peptides could
also favour their penetration into the lipid bilayer of the cell mem-
brane. Comparing the anticancer activity of the designed peptides
with literature data revealed similar anticancer activity against
HeLa cells exerted by GI-15 and a peptide with closely related
structure designed by Chen et al [42,54], named G3, with the
sequence G(IIKK)3I-NH2 (IC50: 16.6 mM vs. 15–16 mM for GI-15
and G3 respectively). On the other hand, CI-15 exhibited 5 times
higher anticancer potency against HeLa cells compared to G3
(IC50: 2.7 mM vs. 15–16 mM for CI-15 and G3 in order) while still
maintaining low toxicity against fibroblasts. Hence, replacing the
N-terminal glycine with Cysteine enhances the anticancer activity
of this group of peptides while maintaining their selectivity for
cancer cells.
The selective cytotoxicity of the designed ACPs towards HCT
116 and HeLa was further confirmed by cell proliferation assays
demonstrating a reduction in the cell population of the cancer cells
treated with IK-13, LK-13, CI-15 and GI-15 compared to the
untreated controls and also changes to the morphology of the cells
(shrinkage of the pre-apoptotic cells) whereas the HDF cells were
less affected by the ACPs (Fig. 3). In a similar fashion to the MTT
assay, CI-15 and GI-15 were found to be equally effective against
both HCT 116 and HeLa whereas IK-13 and LK-13 were more effec-
tive against HCT 116. IR-13 which lacked any significant anticancer
activity in the experimental range of concentrations and LR-13
which lacked any selectivity for cancer cells were not included in
this experiment.
Fig. 2. Cytotoxicity of the cationic amphiphilic peptides in HCT 116 (A), HeLa (B), and HDF (C) as determined by MTT assay. (D) Maximum growth inhibition achieved by the
cationic amphiphilic peptides (at the concentration of 100 mM) in different cell lines. All values were normalized compared to the untreated controls and reported as
Mean ± SE of 6 repeats.
Table 2
Half maximal inhibitory concentration (IC50) values of the designed cationic
amphiphilic peptides in different cell lines as determined by MTT assay. All values
are reported as Mean ± SD of 6 replicates.
Peptide IC50 (mM)
HCT 116 HeLa HDF
IK-13 29 ± 6 47 ± 5 > 100
LK-13 23 ± 2 83 ± 9 > 100
IR-13 > 100 > 100 22 ± 3
LR-13 15.6 ± 1.0 26.7 ± 1.3 24 ± 5
CI-15 7.7 ± 0.2 2.7 ± 0.5 83 ± 5
GI-15 13.6 ± 0.2 16.6 ± 0.8 81 ± 8
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The role of hydrophobicity and helicity of the peptides in deter-
mining their anticancer activity/selectivity is further visualized by
the correlation plots depicted in Fig. 4. As it could be observed,
there was a strong correlation between the anticancer activity of
the peptides in HCT 116 and their helical content in the negatively
charged DPPG lipid bilayers which mimic the cancer cell mem-
branes. Similarly, the cytotoxicity of the peptides against HDF
was well correlated to their helical content in the zwitterionic
DPPC lipid bilayers which are a mimic of the normal mammalian
cell membranes. This is in agreement with the results reported
Fig. 3. High content images of HCT 116, HeLa, and HDF cells treated with the anticancer peptides (100 mM for 72 h) compared to the untreated controls (CRL). The nuclei are
stained with Hoechst 33342 (blue) and actin is stained with Phalloidin (red).  20 magnification, scale bar: 100 mm.
Fig. 4. Correlation between the cytotoxicity of the cationic amphiphilic peptides in HCT 116 (A) and HDF (B) and their helical content in DPPG and DPPC SUVs, respectively.
Relationship between the cytotoxicity of the cationic amphiphilic peptides in HCT 116 (C) and HDF (D) and their hydrophobicity as determined by RP-HPLC retention times.
The values of half maximal inhibitory concentration (IC50) were reported as the average of 6 repeats and the values of mean residue molar ellipticity (h) were reported as the
average of 3 repeats.
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by Chen et al for anticancer peptides with closely related struc-
tures, named G3 and G4, with the sequences G(IIKK)3I –NH2 and
G(IIKK)4I-NH2 respectively [54]. Similar results were reported by
Gong et al for another group of ACPs derived from G3 (i.e., G
(ILKK)3I-NH2, G(IVKK)3I-NH2, G(IVKO)3I-NH2) [39].
The cytotoxicity of the cationic amphiphilic peptides in HCT 116
was also very well correlated with their hydrophobicity and the
more hydrophobic peptides exhibited the strongest anticancer
activity. This is consistent with the studies by Kim et al [70] and
Gong et al [39] who reported a strong correlation between the
hydrophobicity of the a-helical AMPs, as determined by their RP-
HPLC retention times, and their antimicrobial activity [39,70]. In
HDF cells, on the other hand, there was a poor correlation between
hydrophobicity and cytotoxicity, and no specific pattern was
observed. Nevertheless, a closer look at the plot reveals that the
cytotoxicity of the lysine-rich peptides against fibroblasts
increased with their hydrophobicity although the differences were
not significant. Hence, it could be deducted from these data that
the anticancer activity of the designed cationic amphiphilic pep-
tides is determined by both their hydrophobicity and their helical
content whereas their selectivity towards cancer cells is mainly a
function of their helical content in the zwitterionic membrane of
the normal cells and hydrophobicity plays a minor role in it.
3.4. Cytotoxicity of the ACPs in 3D multicellular tumour spheroids
(MCTSs)
Following cytotoxicity tests in 2D cell culture, the anticancer
activity of the designed cationic amphiphilic peptides was further
assessed in 3D MCTSs made of HCT 116 as a mimic of colorectal
adenocarcinoma. MCTSs mimic the 3D cellular context of the solid
tumours and possess features resembling in vivo tumours such as
cell-to-cell contact, excretion of extracellular matrix (ECM), devel-
opment of pH, oxygen and metabolic gradients [76–79]. Therefore,
they are superior to 2D cell culture systems in reflecting the
tumour tissue’s response to drugs and bridge the gap between
the 2D cell culture and animal models [77–79]. Although 3DMCTSs
have been used for evaluating the efficacy of conventional anti-
cancer drugs, there have been very few reports on the efficacy of
anticancer peptides in MCTSs which has been limited to mela-
noma, glioblastoma and lung tumour MCTSs [80–84]. To the best
of our knowledge, this is the first study on the efficacy of ACPs in
colorectal adenocarcinoma MCTSs.
As it could be observed in Fig. 5, two of the designed peptides,
CI-15 and GI-15, which had the strongest anticancer effect against
HCT 116 in 2D cell culture also exhibited considerable anticancer
activity in HCT 116 MCTSs manifested by a significant reduction
in the spheroid size and presence of more dead cells in the spher-
oid core compared to untreated spheroids. The other peptides were
unable to induce any apparent cytotoxicity in MCTSs at the exper-
imental condition. It is also noteworthy that the concentration of
the ACPs required for achieving an observable anticancer effect
in 3D MCTSs was significantly higher than that required for 2D cell
culture. Hence, lack of anticancer activity in MCTSs by IK-13 and
LK-13 could be attributed to the weaker anticancer activity of these
two peptides compared to CI-15 and GI-15 based on their IC50 val-
ues in HCT 116. It is supposed that for these peptides to be able to
exhibit any apparent anticancer activity in MCTSs, considerably
higher concentrations may be required.
3.5. Surface activity of the cationic amphiphilic peptides determines
their anticancer activity
The amphiphilic activities of the designed ACPs were further
measured by their surface adsorption at the air/water interface,
which resulted in a decrease in the surface tension from that of
pure water/buffer, defined as surface pressure, which is indicative
of the surface activity of the peptides. The surface activity experi-
ments were only performed on the peptides with higher selectivity
for cancer cells. Nevertheless, IR-13 which had poor anticancer
activity was also tested as a negative control for comparison. As
it could be observed in Fig. 6A, adsorption of the ACPs at the air–
water interface resulted in increased surface pressure the extent
of which was directly proportional to the concentration of the pep-
tides in the subphase. Thus, the observed interfacial adsorption of
the peptides was concentration dependent. The increase in the sur-
face pressure upon interfacial adsorption of the ACPs was in line
with their anticancer activity. The peptides with stronger anti-
cancer activity gave rise to higher surface pressure (Fig. 6) while
IR-13, which has poor anticancer activity, induced considerably
lower surface pressure than other peptides. There was a strong cor-
relation between the increase in surface pressure by the ACPs and
their helical content in SDS micelles (R2 = 0.73) suggesting that the
same conformational changes that occur at the curved oil–water
interface of the SDS micelles may occur upon adsorption of the
peptides at the air/water interface. These conformational changes
allow for orientation of the hydrophilic surface of the a-helix in
the aqueous subphase and projection of the hydrophobic surface
of the a-helix outside the water in the air. Similar observations
have been reported by other studies with other types of a-helical
cationic amphiphilic peptides [42,85]. The surface pressure of the
ACPs at the air/water interface was also well correlated with their
hydrophobicity (R2 = 0.79). Hence, the surface pressure of the a-
helical peptides at the air–water interface is governed by an inter-
play between their hydrophobicity and their helical content.
3.6. Penetration of the cationic amphiphilic peptides into lipid
monolayers as a mimic of normal and cancer cell membranes
As mentioned earlier, it is generally believed that the mecha-
nism of selectivity of the ACPs for cancer cells is mainly via target-
ing the cancer cell membranes. In order to confirm that the
observed selectivity of the designed ACPs for cancer cells lies in
their higher affinity for cancer cell membranes, the anionic DPPG
monolayers and the zwitterionic DPPC monolayers were used as
in vitro models of the outer leaflet of cancer and normal cell mem-
branes respectively [54,66,86,87]. The insertion of the cationic
amphiphilic peptides into lipid monolayers was studied by moni-
toring the changes to the surface pressure over time following
injection of the peptide solution under the lipid monolayer at a
constant surface area. The experiments were performed at an ini-
tial surface pressure of 28 mN/m which is close to the resting pres-
sure of the mammalian cell membrane [42,54,66]. The peptides
with higher selectivity for cancer cells (IK-13, LK-13, CI-15, and
GI-15) were included in these experiments to investigate the cor-
relation between their biological activity and their interfacial
behaviour.
As it could be observed in Fig. 7, the peptides exhibited a greater
tendency to interact with the anionic DPPG monolayer compared
to the zwitterionic DPPC monolayer except for IR-13 which
showed a preference for DPPC over DPPG. It is suggested that the
stronger electrostatic interaction between the cationic peptides
and the anionic phospholipids facilitates their insertion into the
DPPG lipid monolayer. The binding of the short cationic amphiphi-
lic peptides to the lipid monolayers involves two steps; initial
binding/adsorption of the peptide to the lipid monolayer happens
through electrostatic interactions between the positively charged
amino acid residues and the negatively charged phospholipid
headgroups. Subsequently, hydrophobic interactions between the
hydrophobic amino acid residues and the acyl chains of the phos-
pholipid disturbs the acyl chain ordering and results in increased
surface pressure [85,88].
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The observed trend for the increase in the surface pressure of
the DPPG lipid monolayers upon interaction with the ACPs was
consistent with the observed anticancer activity of the peptides
(R2 = 0.99). Similarly, a good correlation was found between the
toxicity of the peptides in HDFs and the increase in the surface
pressure upon injection of the peptides under DPPC lipid monolay-
ers (R2 = 0.89). The order of increase in the surface pressure follow-
ing interaction of the ACPs with DPPG monolayer was directly
Fig. 5. Cytotoxicity of the anticancer peptides in HCT 116 multicellular tumour spheroids (MCTSs). The green colour (Cyto 9) marks the healthy cells, and the red colour
(propidium iodide) indicates the dead cells.
Fig. 6. Increase in surface pressure at the air- water interface following injection of different concentrations of cationic amphiphilic peptides (A). Correlation between the
anticancer activity of the cationic amphiphilic peptides in HCT 116 and increase in surface pressure upon adsorption of the peptides (at the concentration of 40 mM) at the air
water interface (B). Correlation between the surface pressure of the cationic amphiphilic peptides and their helical content in SDS micelles (C). Correlation between the
surface pressure of the cationic amphiphilic peptides and their hydrophobicity as determined by RP-HPLC retention times (D). The values of pressure (p) and mean residue
molar ellipticity (h) are reported as the average of 3 repeats. The values of half maximal inhibitory concentration (IC50) are reported as the average of six repeats.
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proportional to their helicity in DPPG SUVs (R2 = 0.86). Hence, it is
suggested that similar conformational changes that occur upon
contact of the ACPs with DPPG lipid bilayers may also happen upon
their contact with DPPG lipid monolayers facilitating their penetra-
tion into the DPPG monolayer. Another factor contributing to the
higher adsorption and subsequently penetration of CI-15 and GI-
15 into the DPPG monolayers compared to the other peptides of
shorter length in this group could be the decreased entropy per
amino acid as it has been evidenced that unlike the proteins, for
the peptides the entropy penalty for binding to lipid mono and
bilayers is decreased by increasing the length of the peptide
[89,90].
On the other hand, although the ACPs with low toxicity in HDFs
generally had low helical content in DPPC SUVs and low surface
pressure upon interaction with DPPC lipid monolayers, the rela-
tionship between their helicity and their surface pressure in DPPC
was not linear. It is therefore supposed that the interaction of the
designed ACPs with the zwitterionic DPPC lipid monolayers is
more directed by the hydrophobic interactions between the
hydrophobic domain of the peptide and the acyl chains of the
phospholipids and the conformational change plays a less impor-
tant role in it.
Overall, the lower values of pressure in DPPC monolayers com-
pared to DPPG monolayers indicates weaker interactions of the
peptides with the zwitterionic lipids. These observations further
confirm the previously mentioned hypothesis that the penetration
of the cationic amphiphilic peptides into the phospholipid mono-
layers is a two-step process and that the stronger electrostatic
interactions between the positively charged peptides and the neg-
atively charged headgroups of DPPG compared to the zwitterionic
headgroups of DPPC plays an important role in higher affinity of
the peptides for penetration into DPPG lipid monolayers. Although
the lipid monolayers are limited in providing information about
the exact mechanism of material transport across the cell mem-
brane as they only serve as a model for the outer leaflet of the cell
membrane, the suggested adsorption mechanism and the confor-
mational changes associated with penetration of the ACPs into
the phospholipid monolayers are considered to be essential for
the subsequent translocation of the peptides across the cell mem-
brane and to direct the cellular uptake of the peptides by different
types of cells.
3.7. Higher cellular uptake of the cationic amphiphilic peptides by
cancer cells compared to normal cells indicates their selectivity for
cancer cells
The cell membrane disruption resulting from interaction of the
ACPs with the phospholipids in the cell membrane, eventually dic-
tates the extent of cell penetration of the peptides. The weak inter-
action of the cationic amphiphilic peptides with the cell membrane
of normal cells leads to low cellular uptake of these peptides which
could be one of the reasons for the lower toxicity of these peptides
in normal cells compared to cancer cells. To confirm this assump-
tion, the cationic amphiphilic peptide GI-15 labelled with the fluo-
rescent probe Alexa FluorTM 594 was added to HCT 116 and HDF
cells and its cellular uptake was tracked. As it could be observed
in Fig. 8, the higher intensity and greater distribution of the red flu-
orescence in the cytoplasm of HCT 116 cells compared to HDF cells
provides compelling evidence for higher cellular uptake of the pep-
tide by HCT 116 compared to HDF. Hence, the charge difference
between the cancer cell membranes and normal cell membranes
not only provides a basis for cancer cell targeting but also leads
to increased intracellular concentrations of the peptides in cancer
cells compared to normal cells, which in return reduces the
amount of peptide required for achieving cytotoxicity as reflected
by lower values of IC50 for the peptides in cancer cells compared
to fibroblasts. These observations further indicate the increased
peptide transport across the anionic membrane of the cancer cells
which is in agreement with the higher binding affinity and higher
Fig. 7. (A, D) Increase in the pressure of the DPPG and DPPC lipid monolayers upon injection of the cationic amphiphilic peptides (at the concentration of 20 mM) in the
subphase. (B, E) Correlation between cytotoxicity of the ACPs in HCT 116 or HDF and increase in the surface pressure of DPPG or DPPC lipid monolayers, respectively. (C, F)
Correlation between the increase in the surface pressure of DPPG and DPPC lipid monolayers upon injection of the ACPs and the peptide helicity in DPPG and DPPC SUVs,
respectively. The values of pressure (p), increase in pressure (Dp), and mean residue molar ellipticity (h) are reported as the average of 3 repeats. The values of half maximal
inhibitory concentration (IC50) are reported as the average of 6 repeats.
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penetration of the peptides in DPPG lipid monolayers as discussed
in Section 3.6.
3.8. The cationic amphiphilic peptides exert their cytotoxicity by
damaging the mitochondria
In order to unravel the mechanism of anticancer activity of the
designed ACPs, their interaction with the mitochondrial mem-
branes was investigated by assessing the mitochondrial membrane
depolarization following treatment with the peptides. The mito-
chondrial membrane depolarization/disruption which leads to
apoptosis has been reported as one of the common mechanisms
of action for various ACPs. The high affinity of the ACPs for mito-
chondrial membrane is supposed to be due to its high content of
negatively charged lipids such as cardiolipin [30,32,33,36,37]. The
peptides which showed high selectivity for cancer cells in the via-
bility tests (IK-13, LK-13, CI-15, and GI-15) were tested for their
ability to induce mitochondrial membrane disruption in HCT 116
cells compared to HDF cells.
Fig. 9 shows the images of the HCT 116 and the HDF cells
stained with JC-1 mitochondrial probe following treatment with
the ACPs. JC-1 is a membrane permeant dye and its accumulation
in the mitochondria depends merely on the mitochondrial mem-
brane potential [91,92]. Accumulation of JC-1 in healthy mitochon-
dria results in red fluorescence from the JC-1 aggregates [93,94].
On the other hand, depolarization of the mitochondrial mem-
branes, which is a distinctive feature of the early stages of apopto-
sis, results in reduced accumulation of JC-1 in the mitochondria
manifested by green fluorescence from JC-1 monomers [93,94].
As it could be observed the ACPs damaged the mitochondrial mem-
branes of the HCT 116 cells to a great extent as denoted by higher
proportion of green fluorescence compared to red fluorescence. On
the contrary, in HDFs the red fluorescence from healthy mitochon-
dria was dominating, indicating less damage to the mitochondrial
membrane. This is consistent with lower cellular uptake and lower
cytotoxicity of the ACPs in fibroblasts compared to cancer cells as
discussed earlier. Hence, the designed ACPs exert their anticancer
activity by damaging the mitochondrial membranes which would
eventually lead to apoptosis.
4. Conclusion
A series of short cationic amphiphilic a-helical peptides with
selective anticancer activity were designed and their structure–ac-
tivity relationship was studied. The peptides had strong anticancer
activity against colorectal cancer cells, cervical cancer cells and col-
orectal cancer MCTSs with minimal toxicity against normal non-
cancerous cells (human dermal fibroblasts). Our designed
peptides have modified structures compared to the other anti-
cancer peptides reported in the literature which has resulted in
higher selectivity against cancer cells and in some cases even
higher potency compared to other peptides reported elsewhere
[42,54]. The higher selectivity of the peptides for the cancer cells
was attributed to their higher tendency to interact with the nega-
tively charged membrane of the cancer cells compared to the zwit-
terionic membrane of normal cells. This is consistent with the
literature data suggesting cancer cell membrane targeting as the
main mechanism of cell selectivity for ACPs [30–34,36,37]. The
peptides exerted their cytotoxicity by damaging the mitochondrial
membrane which eventually led to apoptosis, which has been
reported frequently as one of the main mechanisms of cytotoxicity
of many anticancer peptides [30,32,33,36,37]. The anticancer activ-
ity of the peptides was directly proportional to their helical con-
tent, hydrophobicity and surface activity which is in agreement
Fig. 8. Cellular uptake of Alexa FluorTM 594 labelled GI-15 (red) in HCT 116 and HDF cells compared to untreated controls. The nuclei are stained with Hoechst 33342 (blue).
Fig. 9. Mitochondrial membrane depolarization by cationic amphiphilic peptides in HCT 116 (top panel) and HDF cells (bottom panel) as determined by JC-1 mitochondrial
probe. The red fluorescence indicates healthy mitochondria, and the green fluorescence indicates damaged mitochondria in pre-apoptotic cells.
R. Hadianamrei, Mhd Anas Tomeh, S. Brown et al. Journal of Colloid and Interface Science 607 (2022) 488–501
498
with the results from studies on other types of helical anticancer
peptides [39,42,54,70]. The toxicity of peptides in normal cells
was mainly affected by the composition of the hydrophilic domain
of the peptides with lysine being more favourable than arginine. It
was found that addition of isoleucine residues to the C-terminal
and a cysteine residue to the N-terminal of the peptides signifi-
cantly enhanced their anticancer activity while maintaining low
toxicity in normal cells. These findings provide a basis for rational
design of new anticancer peptides with enhanced potency and
selectivity through modification of the peptide structure and
physicochemical properties. Based on the current findings, it is
suggested that in the future attempts for rational design of short
a-helical anticancer peptides, the lysine residues would be
included in the cationic domain of the peptide instead of arginine
residues to avoid the cytotoxic effect of arginine residues on nor-
mal cells. Furthermore, presence of a hydrophobic amino acid resi-
due such as isoleucine in the C-terminal of these peptides is more
favourable than a hydrophilic amino acid residue such as lysine.
Moreover, where stronger helical conformation is desirable, inclu-
sion of cysteine residue in the N-terminal of the peptide is recom-
mended. Future work will be aimed at more in depth study of the
interaction of the designed anticancer peptides with different cell
membranes in order to shed more light on the molecular mecha-
nisms behind specific cell selectivity and also the exact mechanism
of membrane translocation of the peptides. Further modification of
the peptide sequences to investigate the effect of other types of
structural modifications on the biological activity of this class of
peptides is another area to be covered by further studies.
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